ClinicalTrials.gg
Not yet recruitingNCT07273513SMART IIUpdated Dec 18, 2025

"Smart Family Doctor" Assisted Comprehensive Management of Secondary Prevention Among Post Revascularization Patients

An interventional study of Smart family doctor and Health manager in Hypertension, Diabete Mellitus and Hyperlipidemia, sponsored by China National Center for Cardiovascular Diseases. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by China National Center for Cardiovascular Diseases · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
951
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Hypertension by China National Center for Cardiovascular Diseases — 8 open to participants now, 9 under way, none of them phase 3. Hypertension · China National Center for Cardiovascular Diseases.

Planned enrollment
7th of 16
951 · median 480
Started
2026
with 2 others
No phase
13 of 17
6 open now
Registered
14th of 17
by date

Among the 17 studies in Hypertension by China National Center for Cardiovascular Diseases, this one is the 7th largest by planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2026, is one of 13 with no phase, and was the 14th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

8 of the 17 studies in Hypertension by China National Center for Cardiovascular Diseases are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Hypertension by China National Center for Cardiovascular Diseases, or all of them as a file.
02

Study summary

This study aims to evaluate the effect of an AI-assisted "Smart family doctor" digital health management tool on improving the control rates of hypertension, diabetes, and dyslipidemia in post-revascularization patients. A randomized controlled trial design will be used, involving approximately 10-20 hospitals and 951 participants. Eligible participants are adults aged between 18 and 80 years, post-CABG or post-PCI patients with hypertension, diabetes, and dyslipidemia.

03

Conditions studied

  • Hypertension
  • Diabete Mellitus
  • Hyperlipidemia
  • Post PCI
  • Post CABG

Keywords

  • smartphone
  • AI-assisted
  • Revascularization management
  • metabolic management
  • Smart family doctor
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-80 years.
  • Underwent CABG or PCI more than 3 months prior and have concurrent hypertension, diabetes, and dyslipidemia.
  • At least one of the following criteria is meet:
  • Systolic blood pressure no less than 130 mmHg or diastolic blood pressure no less than 80 mmHg
  • no less than 7%
  • LDL-C no less than 1.4 mmol/L
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • History of heart failure or severe arrhythmias.
  • Presence of other severe underlying conditions such as cancer or liver and kidney insufficiency.
  • Pregnancy, lactation, or plans for pregnancy within the next year.
  • Cognitive, communication impairments, or limitations in daily activities.
  • Unable to use smartphone.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
951 participants (estimated)

Study arms

  • Experimental
    "Smart family doctor" assisted management

    "Smart family doctor", an AI-assisted applications with personalized interactions in 24 hours and 7 days a week.

    Behavioral: Smart family doctor

  • Experimental
    Health managers

    3-hour health management guidance from a health manager once a week.

    Behavioral: Health manager

  • Placebo comparator
    Usual care

    Usual post-surgery management

    Behavioral: Usual Care

Interventions

  • BehavioralSmart family doctor

    Participants will be provided "Smart family doctor", which is an AI-assisted applications with personalized interactions. The content includes, but is not limited to: (1) General educational content, covering basic health knowledge on diseases, risk factors, and treatment methods; (2) Targeted health information, such as more specific guidance on blood pressure and blood sugar control, medication adherence, exercise, and smoking cessation; (3) Personalized disease management guidance, providing tailored reminders for patients regarding medication, diet, exercise, and medical visits. Patients can also directly report their latest self-measured blood pressure, blood lipid, blood sugar levels, and medication adherence to receive treatment and medication guidance from the 'Smart family doctor'.

  • BehavioralHealth manager

    Participants will received 3-hour health management guidance from a health manager once a week, including guidance on healthy lifestyle, medication treatment, and rehabilitation advice.

  • BehavioralUsual Care

    Participants will receive usual secondary prevention management.

06

What researchers measure

Primary outcomes

  1. The control rates of hypertension, diabetes and hyperlipidemia

    All cretria are meet: 1) Systolic blood pressure less than 130 mmHg and diastolic blood pressure less than 80 mmHg. 2) HbA1c less than 7%. 3) LDL-C less than 1.4 mmol/L.

    Time frame: 6-month

Secondary outcomes

  1. Blood Pressure Control Rate

    The proportion of patients with systolic blood pressure less than 130 mmHg and diastolic blood pressure less than 80 mmHg.

    Time frame: 6-month

  2. Blood glucose Control Rate

    The proportion of patients with HbA1c less than 7%.

    Time frame: 6-month

  3. Blood lipid Control Rate

    The proportion of patients with LDL-C less than 1.4mmol/L.

    Time frame: 6-month

  4. Systolic blood pressure

    Systolic blood pressure measured at the local site.

    Time frame: 6-month

  5. Diastolic blood pressure

    Diastolic blood pressure measured at the local site.

    Time frame: 6-month

  6. Fasting blood glucose

    Fasting blood glucose analyzed at central lab.

    Time frame: 6-month

  7. HbA1c

    HbA1c analyzed at central lab.

    Time frame: 6-month

  8. Total cholesterol

    Total cholesterol analyzed at central lab.

    Time frame: 6-month

  9. LDL-C

    LDL-C analyzed at central lab.

    Time frame: 6-month

  10. HDL-C

    HDL-C analyzed at central lab.

    Time frame: 6-month

  11. Triglycerides

    Triglycerides analyzed at central lab.

    Time frame: 6-month

  12. Medication adherence (4-item Morisky Medication-Taking Adherence Scale)

    Medication adherence measured by MMAS-4. The score range from 0 to 4. The higher score indicated the better medication adherence.

    Time frame: 6-month

  13. Coronary artery disease-related quality of life (the Seattle Angina Questionnaire)

    Coronary artery disease-related quality of life assessed with the Seattle Angina Questionnaire (SAQ). The score range from 0 to 100. The higher score indicated the better coronary artery disease-related quality of life.

    Time frame: 6-month

  14. Smoking Rate

    The proportion of patients who have smoked within the past month.

    Time frame: 6-month

Other outcomes

  1. Major adverse cardiovascular events (MACE)

    The composite endpoint of cardiovascular death, myocardial infarction, stroke, or hospitalization due to cardiovascular disease.

    Time frame: 6-month

  2. BMI

    Body mass index (BMI) is calculated as weights (kg) divided by the square of heights (meters).

    Time frame: 6-month

  3. Waist circumference

    Waist circumference is measured at local site.

    Time frame: 6-month

  4. Rehospitalization rate

    The proportion of patients who had hospitalization

    Time frame: 6-month

  5. The number of emergency visit

    The number of emergency visit during follow-up period

    Time frame: 6-month

  6. System usability (system usability scale)

    System usability measured by system usability scale. The proportion of patients who scaled system usability more than 68 points.

    Time frame: 6-month

  7. Subgroup-age

    Primary outcome analyses in age subgroups: \<=65, \>65 years

    Time frame: 6-month

  8. Subgroup-sex

    Primary outcome analyses in sex subgroups: women, men

    Time frame: 6-month

  9. Subgroup-education level

    Primary outcome analyses in education level subgroups: less than high school, high school or higher

    Time frame: 6-month

  10. Subgroup-smoking status

    Primary outcome analyses in smoking status subgroups: current smoking, no smoking

    Time frame: 6-month

  11. Subgroup-baseline BP level

    Primary outcome analyses in baseline BP level subgroups: SBP/DBP\>=130/80 mmHg, \<130/80 mmHg

    Time frame: 6-month

  12. Subgroup-baseline LDL-C level

    Primary outcome analyses in baseline LDL-C level subgroups: \<1.4 mmolL, \>=1.4 mmol/L

    Time frame: 6-month

  13. Subgroup-baseline HbA1c level

    Primary outcome analyses in baseline HbA1c level subgroups: \<7%, \>=7%

    Time frame: 6-month

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Anonymized data that support the findings of this study are available from the corresponding author, upon reasonable request, only for authorized research. Their use is subjected to an agreement with the promotor (Fuwai Hospital) and the principal investigator (Dr Xin Yuan) of the SMART II study. Pseudonymised data that support the findings of this study are available from the promotor (Fuwai Hospital) upon reasonable request, subject to a specific agreement with the promotor (involving the principal investigator) and subject to regulatory proceedings due to data protection applicable laws. Access conditions are to be determined depending on the nature of the request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: At the end of the study

Access criteria: Anonymized data that support the findings of this study are available from the corresponding author, upon reasonable request, only for authorized research. Their use is subjected to an agreement with the promotor (Fuwai Hospital) and the principal investigator (Dr Xin Yuan) of the SMART II study. Pseudonymised data that support the findings of this study are available from the promotor (Fuwai Hospital) upon reasonable request, subject to a specific agreement with the promotor (involving the principal investigator) and subject to regulatory proceedings due to data protection applicable laws. Access conditions are to be determined depending on the nature of the request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Dec 2026, 11 months later.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 11 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2025
First posted
Dec 9, 2025
StartEst.
Jan 15, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jan 15, 2027
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07273513
Responsible party
Xin Yuan (Professor, China National Center for Cardiovascular Diseases) — Principal investigator
First posted
Dec 9, 2025
Start date
Jan 15, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Jan 15, 2027 (estimated)
Last update
Dec 18, 2025

Study contacts

Lihua Zhang, PhD
Contact
zhanglihua@fuwai.com
8601060866780
Xin Yuan, PhD
principal investigator · Chinese Academy of Medical Sciences, Fuwai Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion